Evommune, Inc. Basic Shares Outstanding (Weighted Average)
Evommune, Inc. (EVMN) reported Basic Shares Outstanding (Weighted Average) of 36.14 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Evommune, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 36.14M shares, a 2245.41% increase year-over-year.
- Evommune, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 33.67M shares, a 2093.54% increase year-over-year.
- Evommune, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 19.93M shares, a 1203.85% increase year-over-year.
- Evommune, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 1.55M shares, a 1.59% increase year-over-year.
- Evommune, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 6.14M shares, a 306.86% increase from fiscal 2024.
- Evommune, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 1.51M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 36.14M shares 10-Q · filed 2026-08-06 | 34.91M shares 10-Q · filed 2026-08-06 | 29.91M shares derived: average of 3 quarters · filed 2026-08-06 | 22.82M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 33.67M shares 10-Q · filed 2026-05-07 | 26.80M shares derived: average of 2 quarters · filed 2026-05-07 | 18.38M shares derived: average of 3 quarters · filed 2026-05-07 | 14.17M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 19.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 10.74M shares derived: average of 2 quarters · filed 2026-03-05 | 7.67M shares derived: average of 3 quarters · filed 2026-08-06 | 6.14M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 1.55M shares 10-Q · filed 2025-12-11 | 1.54M shares derived: average of 2 quarters · filed 2026-08-06 | 1.54M shares 10-Q · filed 2025-12-11 | 1.54M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 1.54M shares 10-Q · filed 2026-08-06 | 1.54M shares 10-Q · filed 2026-08-06 | 1.53M shares derived: average of 3 quarters · filed 2026-08-06 | 1.53M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 1.53M shares 10-Q · filed 2026-05-07 | 1.53M shares derived: average of 2 quarters · filed 2026-05-07 | 1.53M shares derived: average of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | 1.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 1.52M shares derived: average of 2 quarters · filed 2026-03-05 | 1.51M shares 10-K · filed 2026-03-05 | |
| 2024-09-30 | 1.52M shares 10-Q · filed 2025-12-11 | 1.50M shares 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |